Vivera announced today that it received a third U.S. patent for its Zicoh electronic dose-controlled drug delivery device portfolio.
Newport Beach, California–based Vivera’s latest patent from the U.S. Patent and Trademark Office (USPTO) secures Zicoh’s rights as a smart dosing system with automated delivery, measurement, and management for oral format medications, including pills, capsules and tablets.
Vivera said it designed Zicoh to enable real-time communication through the drug supply chain, from manufacturers, distributers and wholesalers to pharmacists, providers, physicians, caregivers and patients. The device can be programmed to dispense the medication dosage type, amount and frequency according to providers’ orders to ensure compliance with prescriptions while implementing controls to help prevent medication misuse and abuse.
Vivera said later versions of the device are set to implement user authentication features like fingerprint authorization and facial recognition to prevent prescription drugs from being diverted. Reminders can be programmed into Zicoh by the pharmacist per a physician’s orders to alert a patient when its time to take their medication.
The company noted that its third patent differs from the previous two as it specifically pertains to dispensing tablets, capsules and pills. The device already has patents as a smart liquid and inhaler delivery device with automation.
Vivera said it plans to have a working prototype for Zicoh in late summer 2022.
“We are proud of the progress we have made on the development of ZICOH’s multiplatform uses and technology,” Vivera CEO and Chair Paul Edalat said in a news release. “The way that Tesla revolutionized the automotive industry, and the way Apple created a category for smart devices, is what Vivera is doing to the prescription dispensing industry. ZICOH will forever change the way that medications are prescribed and dispensed, and Vivera is reaching the milestones to get there in a fraction of the time projected.”